Publications by the researcher in collaboration with XABIER CAMINO ORTIZ DE BARRÓN (19)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2018

  1. A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients

    Medicina Clinica, Vol. 150, Núm. 8, pp. 291-296

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2010

  1. Factores asociados con la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 4, pp. 215-221

2009

  1. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

    BMC Infectious Diseases, Vol. 10

  2. Genotipado de Chlamydia trachomatis en un área del norte de España

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 27, Núm. 8, pp. 462-464

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2007

  1. Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain

    International Journal of Tuberculosis and Lung Disease, Vol. 11, Núm. 11, pp. 1196-1202

  2. Riesgo elevado de infección por el virus de la inmunodeficiencia humana en varones homosexuales incluso después del contacto con el sistema sanitario

    Enfermeria Clinica, Vol. 17, Núm. 6, pp. 302-308

2000

  1. 70-year-old male with a left laterocervical tumor and fever

    Enfermedades infecciosas y microbiología clínica, Vol. 18, Núm. 9, pp. 473-475